CN104056056A - Traditional Chinese medicine oral liquid for treating leukopenia after chemotherapy - Google Patents
Traditional Chinese medicine oral liquid for treating leukopenia after chemotherapy Download PDFInfo
- Publication number
- CN104056056A CN104056056A CN201410345228.4A CN201410345228A CN104056056A CN 104056056 A CN104056056 A CN 104056056A CN 201410345228 A CN201410345228 A CN 201410345228A CN 104056056 A CN104056056 A CN 104056056A
- Authority
- CN
- China
- Prior art keywords
- parts
- herba
- oral liquid
- ethanol
- chemotherapy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to traditional Chinese medicine oral liquid for treating leukopenia after chemotherapy. The problems that infection is induced due to administration in the process of treating the leukopenia after chemotherapy, the curative effect is instable, the oral liquid is not safe and the cost is high are effectively solved. The traditional Chinese medicine oral liquid is prepared from the following raw material medicines in parts by weight: 10-30 parts of bighead atractylodes rhizome, 12-25 parts of white poria, 10-50 parts of rhizoma polygonati, 10-30 parts of mulberry, 10-20 parts of eclipta, 10-20 parts of glossy privet fruit, 6-15 parts of glaucescent fissistigma root, 10-25 parts of Selaginella doederleinii Hieron, 6-15 parts of herb of glabrous sarcandra and 10-30 parts of Zornia gibbosa. The preparation method comprises the following steps: mixing the raw material medicines, adding water or ethanol, decocting twice, merging the decoctions twice, and filtering to obtain the oral liquid. The traditional Chinese medicine oral liquid has the effects of invigorating spleen and tonifying kidney, detoxifying and dispersing blood stasis and increasing white blood cells, is exact in curative effect in the aspect of improving chemotherapy organism myelosuppression and is an innovation of tumor chemotherapy-assisted medicines.
Description
Technical field
The present invention relates to field of medicaments, particularly a kind of Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy.
Background technology
Tumor is to threaten one of disease that the mankind are the most serious the present age.Operation, radiotherapy and chemotherapy are three Main Means of clinical treatment tumour, and wherein chemotherapy is killed and wounded tumors remaining cell in patient body, can improve curative effect, improves prognosis.But cancer therapy drug lacks special selectivity, in killing cancerous cell, also can kill and wound normal cell, particularly the myeloid element of molecular marker for increased proliferation is suppressed to even more serious, leukopenia is complication common after Chemotherapy in Malignant Carcinoma Patients.Its side effect often makes chemotherapy delay or be forced to interrupt.
At present doctor trained in Western medicine is prevented and treated the bone marrow depression that chemotherapy causes generally low dose of hormonotherapy; Take vitamin, batilol, leucogen's therapy; Repeatedly leukocyte is carried or whole blood conveying in a small amount; Use granulocyte colony-stimulating factor etc.But these Therapeutic Method or have and easily bring out infection, or uncertain therapeutic efficacy cuts, or expense is too high, most of patients such as is difficult to bear at the shortcoming.Therefore, protection bone marrow, leukocyte increasing become a problem in chemotherapy of tumors, and in this regard, Chinese medicine has irreplaceable, unique advantage.
Summary of the invention
For above-mentioned situation, for overcoming prior art defect, the present invention's object is just to provide a kind of Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy, medication can effectively solve treatment leukopenia after chemotherapy time, prevent from bringing out infection, curative effect is unstable, dangerous and problem that expense is high.
The technical scheme that the present invention solves is, it is to be made by the material medicine of following parts by weight meter: Rhizoma Atractylodis Macrocephalae 10-30 part, Poria 12-25 part, Rhizoma Polygonati 10-50 part, Fructus Mori 10-30 part, Herba Ecliptae 10-20 part, Fructus Ligustri Lucidi 10-20 part, Radix Fissistigmatis Glaucescentis 6-15 part, Herba Selaginellae Doederleinii 10-25 part, Herba Sarcandrae 6-15 part and Zornia diphylla (Linn.) Pers. 10-30 part, wherein, by above-mentioned raw materials medicament mixed together, add the water of material medicine 4-6 times weight or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, obtain.
The fluid extract that when Chinese medicine oral liquid of the present invention also can be concentrated into 60 DEG C, relative density is 1.14-1.18, adopts conventional method to make respectively the dosage form of the tablet of auxiliary oncotherapy, granule, capsule, pill, any application of syrup.
The present invention has strengthening spleen, tonifying kidney, eliminating toxic substances to remove stasis, increases effect of leukocyte, is improving aspect the bone marrow depression of chemotherapy body, and curative effect is sure, is the innovation on the medicine of adjuvant for chemotherapy of tumour.
Detailed description of the invention
Below in conjunction with embodiment, the specific embodiment of the present invention is described in further detail.
Embodiment 1
In the specific implementation, oral liquid of the present invention also can be made up of the material medicine of following parts by weight meter: 10 parts of 10 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Porias, 10 parts of Rhizoma Polygonatis, 10 parts, Fructus Mori, 10 parts of Herba Ecliptaes, 10 parts of Fructus Ligustri Lucidi, 6 parts of Radix Fissistigmatis Glaucescentiss, 10 parts of Herba Selaginellae Doederleiniis, 6 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 4 times of weight of material medicine or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, to obtain final product.
Embodiment 2
In the specific implementation, oral liquid of the present invention also can be made up of the material medicine of following parts by weight meter: 20 parts of 20 parts of the Rhizoma Atractylodis Macrocephalaes, 18 parts of Porias, 30 parts of Rhizoma Polygonatis, 20 parts, Fructus Mori, 15 parts of Herba Ecliptaes, 15 parts of Fructus Ligustri Lucidi, 10 parts of Radix Fissistigmatis Glaucescentiss, 18 parts of Herba Selaginellae Doederleiniis, 10 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 5 times of weight of material medicine or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, to obtain final product.
Embodiment 3
In the specific implementation, oral liquid of the present invention also can be made up of the material medicine of following parts by weight meter: 30 parts of 30 parts of the Rhizoma Atractylodis Macrocephalaes, 25 parts of Porias, 50 parts of Rhizoma Polygonatis, 30 parts, Fructus Mori, 20 parts of Herba Ecliptaes, 20 parts of Fructus Ligustri Lucidi, 15 parts of Radix Fissistigmatis Glaucescentiss, 25 parts of Herba Selaginellae Doederleiniis, 15 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 6 times of weight of material medicine or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, to obtain final product.
Embodiment 4
In the specific implementation, oral liquid of the present invention is to be made up of the material medicine of following parts by weight meter: 20 parts of 15 parts of the Rhizoma Atractylodis Macrocephalaes, 20 parts of Porias, 10 parts of Rhizoma Polygonatis, 10 parts, Fructus Mori, 10 parts of Herba Ecliptaes, 15 parts of Fructus Ligustri Lucidi, 15 parts of Radix Fissistigmatis Glaucescentiss, 25 parts of Herba Selaginellae Doederleiniis, 15 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 4 times of weight of material medicine at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first be soaked in water 1 hour, merge 2 times decoction liquor, filter, to obtain final product.
Embodiment 5
In the specific implementation, oral liquid of the present invention is to be made up of the material medicine of following parts by weight meter: 15 parts of 25 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Porias, 40 parts of Rhizoma Polygonatis, 25 parts, Fructus Mori, 15 parts of Herba Ecliptaes, 10 parts of Fructus Ligustri Lucidi, 6 parts of Radix Fissistigmatis Glaucescentiss, 10 parts of Herba Selaginellae Doederleiniis, 6 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, the ethanol that the volumetric concentration that at every turn adds 5 times of weight of material medicine is 70%, decoct 2 times, each 70 minutes, while decoction for the first time, first use soak with ethanol 1 hour, merge 2 times decoction liquor, filter, to obtain final product.
The foregoing is only best case study on implementation of the present invention; only illustrative for the purpose of the present invention; and it is nonrestrictive; those skilled in the art is understood; in the scope of the claims in the present invention, can carry out some to it is equal to or equivalent substituting or replacing; but its essence is identical, all belong to protection scope of the present invention.
The above medicine, wherein:
The Rhizoma Atractylodis Macrocephalae: remove impurity, clean, run through, cut sheet, dry, there is invigorating the spleen and benefiting QI, effect of dampness diuretic, for insufficiency of the spleen lack of appetite, abdominal distention is had loose bowels, phlegm retention vertigo and palpitation, edema, spontaneous perspiration.
Poria: get Poria and soak, clean, after profit, slightly steam, the crust of pruning in time, cutting in bulk or cut sheet, dries, and has promoting diuresis to eliminate damp pathogen, spleen invigorating, effect of mind calming.
Rhizoma Polygonati: remove impurity, clean, slightly profit, cuts sheet, dry, has boosting qi and nourishing yin, spleen invigorating, lung moistening, effect of kidney tonifying.
Fructus Mori: clean, dry the YIN nourishing of enriching blood, the effect of promoting the production of body fluid and moisturizing.For vertigo and tinnitus, palpitation and insomnia, early whitening of beard and hair, Tianjin wound is thirsty, and interior-heat is quenched one's thirst.
Herba Ecliptae: remove impurity, slightly wash, cutting, dry, there is nourishing the liver and kidney, effect of cooling blood for hemostasis, for the hepatic and renal YIN deficiency, odontoseisis, early whitening of beard and hair, vertigo and tinnitus, soreness of the waist and knees, YinXuXueRe.
Fructus Ligustri Lucidi: remove impurity, cleaning, drying, have nourishing the liver and kidney, effect of improving eyesight black hair, for the hepatic and renal YIN deficiency, dizzy ear toot, soreness of the waist and knees, beard and hair drought is white, poor vision, interior-heat is quenched one's thirst, osteopyrexia and fever.
Radix Fissistigmatis Glaucescentis: remove fibrous root, clean, dry, have wind-damp dispelling, the effect that restores menstrual flow and invigorates blood circulation, stops blooding.
Herba Selaginellae Doederleinii: clean, dry, there is heat-clearing and toxic substances removing, expelling wind and removing dampness, hemostasis, the effect such as anticancer.
Herba Sarcandrae: remove impurity, clean, run through, cutting, dry, there is clearing away heat and cooling blood, the speckle removing of invigorating blood circulation, effect of dispelling wind and removing obstruction in the collateral.Send out speckle dermexanthesis, rheumatic arthralgia for heat in blood.
Zornia diphylla (Linn.) Pers.: remove impurity, clean, dry, have heat-clearing and toxic substances removing, removing blood stasis to reduce swelling, has adjusted effect of dampness removing.
From said medicine, all medicine phases 5 of the present invention, have strengthening spleen, tonifying kidney, and effect of eliminating toxic substances to remove stasis, can be effective to the treatment of leukopenia after chemotherapy, and curative effect is sure, and through clinical practice, has obtained good effect, and related tests data is as follows:
One, zoopery
1 materials and methods
60 of 1.1 animals and the clean level of grouping male ICR mouses, body weight 18-22g.
1.2 medicines and instrument cyclophosphamide (CTX), cellanalyzer, Olympus biological microscope, blood cell counting plate.
1.3 modeling
By S180 ascites tumor mice milky ascites, with normal saline dilution to 2 × 10
6individual/mL and viable count are greater than 95%, are inoculated in the right axil of mice subcutaneous with 0.2mL, test in inoculated tumour cell second day.
1.4 method
60 of mices are divided into 4 groups at random, that is: 1, Normal group (0.2m l/10g normal saline), 2, model group (80mg/kg CTX), 3, positive controls (0.03mg/kg recombinant human granulocyte colony stimulating factor), 4, Chinese drug-treated group of the present invention (25g/kg).Totally 14 days experimental period.Normal group, Chinese drug-treated group gastric infusion every day of the present invention 1 time, totally 14 days; Test 8-10 days, except Normal group, remaining each group lumbar injection CTX80mg/kg, every day 1 time; Positive controls mice was in 11-13 days subcutaneous injection recombinant human granulocyte colony stimulating factors.
1.5 testing index peripheral white blood cells and bone marrow nucleated cell counting (BMNC)
1.6 statistical analysis
Experimental result all with
represent, adopt SPSS15.0 statistical package to carry out statistical analysis.Adopt one factor analysis of variance (ANOVA), between group, compare between two, adopt the inspection of LSD method, P < 0.05 has significance for difference.
2 results
With Normal group comparison, model control group WBC, BMNC quantity significantly reduce (P < 0.01); With model control group comparison, Chinese drug-treated group WBC of the present invention, BMNC digital display work rising (P < 0.05); Between positive controls and Chinese drug-treated group of the present invention, compare difference not statistically significant (P > 0.05).
The comparison that the each group of table 1 mouse peripheral blood resembles and bone marrow nucleated cell is counted
With relatively * P < 0.05 * * P < 0.05 of model group
Two, clinical trial data of the present invention is as follows:
1, data and method
1.1 clinical datas:
All patients underwent operative or proved by pathology are malignant tumor.Before chemotherapy, look into hepatic and renal function normal, without disease in the blood system, WBC > 4.0 × 10
9more than/L, all cases all adopt standard chemotherapy regimen [Wang Huaqing, Cui Xiuzhen, Wan Ling, Deng. malignant tumor chemotherapy scheme specification [M] Shenyang: Liaoning science and technology publishing house, 2002:14], double inspection WBC counting < 4.0 × 10 in chemotherapy process
9/ L.All cases is divided into treatment group 40 examples at random, matched group 41 examples.Two groups of sexes, age, sick kind and leukopenia degree (severe: WBC countings≤2.0 × 10
9/ L, moderate: WBC counting≤3.0 × 10
9/ L, slight: WBC counting≤4.0 × 10
9/ L) etc. data learn by statistics comparison, there was no significant difference (P > 0.05), has comparability, specifically in table 2.
The clinical physical data comparison of table 2 treatment group and matched group
1.2 therapeutic scheme
Treatment group: Chinese medicine oral liquid of the present invention, sooner or later respectively once, each 200ml; Matched group: leucogen 20mg, 1d3 time; Adenine phosphate 20mg, 1d3 time; Batilol 50mg, 1d3 time; All oral; Two groups all taking two weeks as one course for the treatment of.
1.3 criterion of therapeutical effect
Drug for increasing white cells criterion of therapeutical effect in " the clinical drug research guideline " formulated with reference to Ministry of Health of the People's Republic of China.Effective: continuous 2 numeration of leukocyte >4.0 × 10 in 1 week
9/ L, and can maintain 1 week; Effective: in 1 week, continuous 2 numeration of leukocyte are front improves 100%, or rises to 3.0 × 10
9/ L, and can maintain 1 week; Invalid: numeration of leukocyte is without obviously increasing.
1.4 therapeutic outcome
Treatment group 40 examples, effective 16 examples, effective 22 examples, invalid 2 examples, total effective rate 95%; Matched group 41 examples, effective 10 examples, effective 23 examples, invalid 8 examples, total effective rate 80.5%.
1.5 conclusion
Can clearly be found out by above-mentioned, Chinese medicine oral liquid of the present invention is better than matched group, and during medication, find no any harmful effect, drug safety, curative effect is sure, up to 95%, cost is low, easily accepted by patient, solved chemotherapy after tumor patient generally there is bone marrow depression, leukopenic problem, be effective to the application in adjuvant for chemotherapy of tumour medicine, there is actual clinical meaning.
Claims (6)
1. treat the Chinese medicine oral liquid of leukopenia after chemotherapy for one kind, it is characterized in that, it is to be made by the material medicine of following parts by weight meter: Rhizoma Atractylodis Macrocephalae 10-30 part, Poria 12-25 part, Rhizoma Polygonati 10-50 part, Fructus Mori 10-30 part, Herba Ecliptae 10-20 part, Fructus Ligustri Lucidi 10-20 part, Radix Fissistigmatis Glaucescentis 6-15 part, Herba Selaginellae Doederleinii 10-25 part, Herba Sarcandrae 6-15 part and Zornia diphylla (Linn.) Pers. 10-30 part, wherein, by above-mentioned raw materials medicament mixed together, add the water of material medicine 4-6 times weight or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, obtain.
2. the Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy according to claim 1, it is characterized in that, material medicine by following parts by weight meter is made: 10 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Porias, 10 parts of Rhizoma Polygonatis, 10 parts, Fructus Mori, 10 parts of Herba Ecliptaes, 10 parts of Fructus Ligustri Lucidi, 6 parts of Radix Fissistigmatis Glaucescentiss, 10 parts of Herba Selaginellae Doederleiniis, 10 parts of 6 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 4 times of weight of material medicine or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, obtain.
3. the Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy according to claim 1, it is characterized in that, material medicine by following parts by weight meter is made: 20 parts of the Rhizoma Atractylodis Macrocephalaes, 18 parts of Porias, 30 parts of Rhizoma Polygonatis, 20 parts, Fructus Mori, 15 parts of Herba Ecliptaes, 15 parts of Fructus Ligustri Lucidi, 10 parts of Radix Fissistigmatis Glaucescentiss, 18 parts of Herba Selaginellae Doederleiniis, 20 parts of 10 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 5 times of weight of material medicine or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, obtain.
4. the Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy according to claim 1, it is characterized in that, material medicine by following parts by weight meter is made: 30 parts of the Rhizoma Atractylodis Macrocephalaes, 25 parts of Porias, 50 parts of Rhizoma Polygonatis, 30 parts, Fructus Mori, 20 parts of Herba Ecliptaes, 20 parts of Fructus Ligustri Lucidi, 15 parts of Radix Fissistigmatis Glaucescentiss, 25 parts of Herba Selaginellae Doederleiniis, 30 parts of 15 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 6 times of weight of material medicine or the ethanol that volumetric concentration is 70% at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first water or soak with ethanol 1 hour, merge 2 times decoction liquor, filter, obtain.
5. the Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy according to claim 1, it is characterized in that, material medicine by following parts by weight meter is made: 15 parts of the Rhizoma Atractylodis Macrocephalaes, 20 parts of Porias, 10 parts of Rhizoma Polygonatis, 10 parts, Fructus Mori, 10 parts of Herba Ecliptaes, 15 parts of Fructus Ligustri Lucidi, 15 parts of Radix Fissistigmatis Glaucescentiss, 25 parts of Herba Selaginellae Doederleiniis, 20 parts of 15 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, add the water of 4 times of weight of material medicine at every turn, decoct 2 times, each 70 minutes, while decoction for the first time, first be soaked in water 1 hour, merge 2 times decoction liquor, filter, obtain.
6. the Chinese medicine oral liquid for the treatment of leukopenia after chemotherapy according to claim 1, it is characterized in that, material medicine by following parts by weight meter is made: 25 parts of the Rhizoma Atractylodis Macrocephalaes, 12 parts of Porias, 40 parts of Rhizoma Polygonatis, 25 parts, Fructus Mori, 15 parts of Herba Ecliptaes, 10 parts of Fructus Ligustri Lucidi, 6 parts of Radix Fissistigmatis Glaucescentiss, 10 parts of Herba Selaginellae Doederleiniis, 15 parts of 6 parts of Herba Sarcandraes and Zornia diphylla (Linn.) Pers., wherein, by above-mentioned raw materials medicament mixed together, the ethanol that the volumetric concentration that at every turn adds 5 times of weight of material medicine is 70%, decoct 2 times, each 70 minutes, while decoction for the first time, first use soak with ethanol 1 hour, merge 2 times decoction liquor, filter, obtain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410345228.4A CN104056056B (en) | 2014-07-19 | A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410345228.4A CN104056056B (en) | 2014-07-19 | A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104056056A true CN104056056A (en) | 2014-09-24 |
| CN104056056B CN104056056B (en) | 2016-11-30 |
Family
ID=
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107303386A (en) * | 2016-04-25 | 2017-10-31 | 高安友 | A kind of preparation method for being used to treat the low oral liquid of leucocyte |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107303386A (en) * | 2016-04-25 | 2017-10-31 | 高安友 | A kind of preparation method for being used to treat the low oral liquid of leucocyte |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1485083A (en) | Capsule for thyroid cancer / tumor and lymph node | |
| JP2004537508A (en) | Antitumor drug | |
| CN101181529B (en) | Chinese medicine composition for curing tumor and preparation method thereof | |
| CN106390013A (en) | Compound traditional Chinese medicine composition capable of inhibiting colorectal liver metastases as well as preparation method and application thereof | |
| CN103861079A (en) | Traditional Chinese medicine composition with effects of clearing heat, relieving pain and eliminating tumors | |
| CN101125178A (en) | Traditional Chinese medicine for treating tumor | |
| CN101711848B (en) | Chinese medicinal composition capable of adjunctively treating tumour | |
| CN1305515C (en) | Chinese medicinal powder and decoction composition for treating cancer | |
| CN102697984B (en) | Chinese medicinal external application preparation for treating acute mastitis | |
| CN109248305A (en) | A kind of Chinese medicine composition and preparation method thereof for treating liver fibrosis | |
| CN105125792A (en) | Traditional Chinese medicinal decoction for treating female mastitis and preparation method of decoction | |
| CN101804175A (en) | Anti-cancer Chinese medicinal powder and preparation method thereof | |
| CN104257883A (en) | Traditional Chinese medicine composition for treating leucopenia after chemotherapy | |
| CN106511915A (en) | Applications of compound traditional Chinese medicinal composition in preparing medicines for inhibiting skin melanoma lung metastasis | |
| CN104056056B (en) | A kind of Chinese medicine oral liquid treating leukopenia after chemotherapy | |
| CN102266434B (en) | Chinese medicinal composition for resisting tumor metastasis and preparation method thereof | |
| CN101979035A (en) | Medicament for treating gynecological abnormal leucorrhea | |
| CN104056056A (en) | Traditional Chinese medicine oral liquid for treating leukopenia after chemotherapy | |
| CN110585401A (en) | Chinese medicinal compound preparation with effects of strengthening body resistance and eliminating pathogenic factors | |
| CN104043085A (en) | Traditional Chinese medicine for treating vomitus gravidarum | |
| CN104042839A (en) | Traditional Chinese medicine composition for treating tinea versicolor | |
| CN108635498B (en) | Pharmaceutical composition for treating myelodysplastic syndrome and application thereof | |
| CN107029111B (en) | Traditional Chinese medicine compound preparation for treating leukemia caused by vital qi deficiency and pathogenic factor latent and preparation method thereof | |
| CN101953943A (en) | Traditional Chinese medicine for treating chronic aplastic anemia | |
| CN107362296B (en) | Medicine for treating benign tumor of skin and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20161130 Termination date: 20170719 |